Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868959 · ClinicalTrials.gov registry record · Phase 3
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 817
- Enrollment target
NCT00868959 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 817 participants.
The verdict
NCT00868959, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 817 participants
- Enrollment target
Study Summary
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
Interventions
- DRUG lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 817 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868959
The ClinicalTrials.gov registry entry for NCT00868959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 817 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lurasidone is the first listed.
NCT00868959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868959 about?
NCT00868959 is a clinical study titled "Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression". This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
What is the current status of trial NCT00868959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 817 participants. The study started on 2009-04. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00868959?
The interventions under investigation include: lurasidone (DRUG).
Who is sponsoring clinical trial NCT00868959?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.